COVID-19
Roche’s Actemra failed to meet its primary and secondary endpoints in a late-stage study involving hospitalized patients with severe COVID-19 associated pneumonia.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 29, 2020.
JLL published its JLL 2020 U.S. Life Sciences Outlook, which ranks and tracks the progress of life sciences markets, particularly in how they relate to real estate development.
Less than one week after forging a vaccine manufacturing agreement with Novavax, FUJIFILM Diosynth Biotechnologies announced its College Station, Texas facility was selected by the federal government to support COVID-19 vaccine candidate manufacturing.
Although COVID-19 primarily presents itself as a respiratory disease, a number of associations have been discovered between the microbiomes and a number of diseases.
The vaccine will be dosed at a 30-microgram level with a two-dose regimen. The vaccine is an mRNA product, with the mRNA encoding for the SARS-CoV-2 full length spike glycoprotein (S).
A number of studies have suggested that people infected with COVID-19 tend to have T cells that can target the virus. However, scientists are now also realizing that some people who can test negative for COVID-19 antibodies can test positive for T cells that identify the virus within the body.
Ebola, HIV and Zika viruses became global challenges that caused researchers and vaccine developers to jump into action but, ultimately, vaccine development takes time. That’s why claims that SARS-CoV-2 vaccines will be available soon often are met with skepticism.
Gaithersburg, Maryland-based Emergent BioSolutions inked another manufacturing agreement to support the development of a vaccine against COVID-19, the disease caused by the novel coronavirus.
Stéphane Bancel, Moderna’s chief executive officer, stated, “We thank BARDA for this continued commitment to mRNA-1273, our vaccine candidate against COVID-19.”
PRESS RELEASES